<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Management of nonmotor symptoms in Parkinson disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Management of nonmotor symptoms in Parkinson disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Management of nonmotor symptoms in Parkinson disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lana Chahine, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Howard I Hurtig, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 15, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Parkinson disease (PD) is a chronic, progressive neurodegenerative disease characterized by bradykinesia (slowness of movement) and hypokinesia (reduced amplitude of movement) combined with rest tremor and/or rigidity. The clinical features most suggestive of idiopathic PD rather than an atypical or secondary parkinsonian syndrome include asymmetric or unilateral onset, the presence of resting tremor, and a clear-cut response to treatment with L-dopa.
        </p>
        <p>
         In addition to these typical motor features, patients with PD may experience nonmotor symptoms related to the disease itself or to the medications used to treat it. These include various neuropsychiatric manifestations including cognitive dysfunction, hallucinations and other psychotic symptoms, anxiety, apathy, and mood disorders such as depression [
         <a href="#rid1">
          1,2
         </a>
         ]. Disorders of sleep and wakefulness are common, including insomnia, parasomnias, restless legs syndrome (RLS), and daytime sleepiness. Autonomic problems are also prominent, including orthostatic hypotension, sexual dysfunction, and constipation.
        </p>
        <p>
         Management of these nonmotor symptoms will be reviewed here. Dementia in PD and the clinical features of nonmotor symptoms in PD are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5089.html" rel="external">
          "Cognitive impairment and dementia in Parkinson disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4903.html" rel="external">
          "Clinical manifestations of Parkinson disease", section on 'Nonmotor symptoms'
         </a>
         .)
        </p>
        <p>
         Other aspects of PD are reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4906.html" rel="external">
          "Epidemiology, pathogenesis, and genetics of Parkinson disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4904.html" rel="external">
          "Diagnosis and differential diagnosis of Parkinson disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4896.html" rel="external">
          "Initial pharmacologic treatment of Parkinson disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4899.html" rel="external">
          "Nonpharmacologic management of Parkinson disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4893.html" rel="external">
          "Medical management of motor fluctuations and dyskinesia in Parkinson disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4897.html" rel="external">
          "Device-assisted and lesioning procedures for Parkinson disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2150235961">
         <span class="h1">
          DEPRESSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Depression is one of the most common psychiatric disturbances seen in PD. Depressive symptoms in PD are associated with increased motor disability and decreased quality of life. (See
         <a class="medical medical_review" href="/z/d/html/4903.html" rel="external">
          "Clinical manifestations of Parkinson disease", section on 'Mood disorders'
         </a>
         .)
        </p>
        <p>
         Patients with depression should be offered antidepressant medication, cognitive behavioral therapy (CBT), or both [
         <a href="#rid2">
          2
         </a>
         ]. Selection is individualized based on patient preferences, access to therapy, and medication profiles and side effects.
        </p>
        <p>
         Importantly, suicidal ideation and thoughts of death are common in PD. In surveys, such thoughts are present in 20 to 33 percent of patients [
         <a href="#rid3">
          3
         </a>
         ], and depression is an important risk factor [
         <a href="#rid4">
          4,5
         </a>
         ]. Though suicide attempts are fortunately uncommon, actively suicidal patients should be hospitalized [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Overviews of depression in adults, including clinical manifestations and treatment, are found separately. (See
         <a class="medical medical_review" href="/z/d/html/1721.html" rel="external">
          "Unipolar depression in adults: Assessment and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">
          "Unipolar major depression in adults: Choosing initial treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H538248046">
         <span class="h2">
          Pharmacotherapy
         </span>
        </p>
        <p class="headingAnchor" id="H3634881311">
         <span class="h3">
          Medication selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the absence of a clear first choice for treating depression associated with PD, drug selection should be based on potential advantages versus potential side effects [
         <a href="#rid1">
          1,6
         </a>
         ]. It is reasonable to start with a selective serotonin-norepinephrine reuptake inhibitor (SNRI) or a selective serotonin reuptake inhibitor (SSRI) in most patients with PD, as the likelihood of adverse events is lower with these agents than with tricyclics such as
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         (and
         <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">
          nortriptyline
         </a>
         , to a lesser extent) [
         <a href="#rid1">
          1
         </a>
         ]. The anticholinergic side effects of tricyclic medications, which can include cognitive impairment and orthostatic hypotension with an increased risk of falls, may be particularly troublesome in the setting of PD [
         <a href="#rid7">
          7
         </a>
         ]. However, for patients who do not improve with SNRI or SSRI treatment, a tricyclic antidepressant is a reasonable option, particularly when tremor is a dominant symptom and the potential benefit is thought to outweigh the risk of anticholinergic side effects.
        </p>
        <p>
         A practice parameter from the American Academy of Neurology (AAN) reviewed six small, randomized controlled trials of pharmacologic treatment for depression in patients with PD [
         <a href="#rid7">
          7
         </a>
         ]. In one of these trials,
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         but not
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         treatment was associated with significant improvement [
         <a href="#rid8">
          8
         </a>
         ]. The AAN found insufficient evidence to support or refute the effectiveness of other antidepressant medications in this setting.
        </p>
        <p>
         Since the AAN report, a number of randomized placebo-controlled trials have reported the following observations regarding the treatment of depression in patients with PD:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">
          Desipramine
         </a>
         and
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         were equally effective [
         <a href="#rid9">
          9
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">
          Nortriptyline
         </a>
         was efficacious while
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         controlled release was not [
         <a href="#rid10">
          10
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">
          Atomoxetine
         </a>
         was not beneficial [
         <a href="#rid11">
          11
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          Paroxetine
         </a>
         and
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         improved depression and did not worsen motor function [
         <a href="#rid12">
          12
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Evidence from other randomized controlled trials suggests that dopamine agonists may improve depressive symptoms in patients with PD [
         <a href="#rid1">
          1,13-15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1894233331">
         <span class="h3">
          Safety considerations with SSRI use
         </span>
         <span class="headingEndMark">
          —
         </span>
         SSRIs and SNRIs are generally safe in patients with PD. However, they can cause QT prolongation, and monitoring for this is essential where indicated, for example, when patients are known to be on other medications that cause QT prolongation and/or in patients with underlying heart disease.
        </p>
        <p>
         Additional considerations include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exacerbation of motor symptoms
         </strong>
         – SSRIs carry a risk of exacerbating motor symptoms. SSRIs may induce or worsen dystonia, akathisia, tremor, and parkinsonism [
         <a href="#rid16">
          16
         </a>
         ]. Patients with increased susceptibility to exacerbation of motor symptoms due to advanced age [
         <a href="#rid17">
          17
         </a>
         ] or higher SSRI plasma levels because of drug-drug interactions [
         <a href="#rid18">
          18
         </a>
         ] may be at greater risk for this complication. However, the risk of these motor complications is relatively low. Three prospective, open-label studies of several different SSRIs in patients with PD with [
         <a href="#rid19">
          19,20
         </a>
         ] or without [
         <a href="#rid21">
          21
         </a>
         ] depression have shown no worsening of quantitative motor scores following treatment lasting one to six months. Among the SSRIs,
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         may be the least likely of SSRIs to worsen motor symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exacerbation of comorbid sleep disorders
         </strong>
         – SSRIs and other antidepressants have the potential to worsen restless legs syndrome (RLS) and rapid eye movement sleep behavior disorder (RBD). Patients starting an SSRI, SNRI, or tricyclic antidepressant must be monitored for emergence or exacerbation of symptoms of RLS and RBD.
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          Bupropion
         </a>
         is commonly used for management of depression in PD, though little evidence supports its use. Of antidepressants, it is least likely to exacerbate RLS and RBD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serotonin syndrome
         </strong>
         – Serotonin syndrome is another uncommon but serious adverse event associated with SSRIs, especially when they are used in conjunction with other medications that can increase serotonin. Serotonin syndrome is a potentially severe condition associated with increased serotonergic activity in the central nervous system and severely disturbed mental, motor, and autonomic function. (See
         <a class="medical medical_review" href="/z/d/html/301.html" rel="external">
          "Serotonin syndrome (serotonin toxicity)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The monoamine oxidase type B (MAO B) inhibitors
         <a class="drug drug_general" data-topicid="9883" href="/z/d/drug information/9883.html" rel="external">
          selegiline
         </a>
         and
         <a class="drug drug_general" data-topicid="10338" href="/z/d/drug information/10338.html" rel="external">
          rasagiline
         </a>
         should be used only at recommended doses and with caution when combined with other antidepressants, including tricyclics and SSRIs, because of the risk of causing the serotonin syndrome [
         <a href="#rid22">
          22
         </a>
         ]. Despite this theoretical risk, movement disorder specialists often use an MAO B inhibitor and an antidepressant for patients with PD without causing serotonin syndrome. The risk of the serotonin syndrome is uncertain but is low. Two chart reviews have shown no serious side effects in a total of 48 patients receiving selegiline and an SSRI [
         <a href="#rid23">
          23,24
         </a>
         ]. Another study surveyed 47 specialists who manage PD and reported that among 4568 patients treated with a combination of selegiline and an antidepressant, symptoms consistent with the serotonin syndrome were observed in only 11 (0.24 percent) [
         <a href="#rid22">
          22
         </a>
         ]. The most reassuring data come from a post hoc analysis of a large randomized controlled trial of rasagiline in PD [
         <a href="#rid25">
          25
         </a>
         ]. Among 1174 patients with early PD randomized to rasagiline or placebo, 191 patients were treated concurrently with antidepressants (76 percent with an SSRI, 21.4 percent with a tricyclic antidepressant). There were no serious adverse events suggestive of serotonin syndrome in the combined rasagiline-antidepressant group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Published and US Food and Drug Administration-reported cases of adverse effects of selegiline-antidepressant combinations are also very few, and most do not fulfill criteria for the serotonin syndrome. At higher-than-recommended doses (ie, &gt;10 mg daily for
         <a class="drug drug_general" data-topicid="9883" href="/z/d/drug information/9883.html" rel="external">
          selegiline
         </a>
         ; &gt;1 mg daily for
         <a class="drug drug_general" data-topicid="10338" href="/z/d/drug information/10338.html" rel="external">
          rasagiline
         </a>
         ) the MAO B inhibitors may also inhibit MAO A and, when given with an antidepressant, carry the risk of the tyramine "cheese" reaction, characterized by a severe hypertensive crisis. However, this reaction is rare when the MAO B inhibitors are given at recommended doses.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1625802840">
         <span class="h2">
          Nonpharmacologic therapies
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Psychotherapy
         </strong>
         – Abundant data in the general population, as well as more limited data in patients with PD, indicate that CBT is also an effective treatment for depression in PD. In a pilot randomized trial of CBT versus observation in eight patients with PD, the CBT group had improved depression scores at 10 weeks [
         <a href="#rid26">
          26
         </a>
         ]. A larger trial of telephone-based CBT in 72 patients with PD found improvements in depression scores over usual care, which were moderated primarily by a decrease in negative thoughts [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the absence of additional evidence specifically in the PD population, data on the treatment of depression in older adults indicate that combining CBT with pharmacotherapy is superior to pharmacotherapy alone for the treatment of depression, and this should be considered in PD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transcranial magnetic stimulation
         </strong>
         – There are data to indicate that transcranial magnetic stimulation may be a useful treatment for depression in patients with PD, especially when used in conjunction with antidepressants [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exercise
         </strong>
         – Exercise can also play a role in improving depression symptoms in patients with PD, along with other benefits. Data on dose and type of exercise that are optimal for depression in PD are limited, but evidence indicates that exercise that includes resistance training [
         <a href="#rid29">
          29
         </a>
         ] and yoga [
         <a href="#rid30">
          30
         </a>
         ] may be of benefit [
         <a href="#rid31">
          31,32
         </a>
         ]. Other nonpharmacologic interventions that may help patients with PD include light therapy [
         <a href="#rid33">
          33
         </a>
         ] and mindfulness techniques such as meditation [
         <a href="#rid34">
          34,35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H47269499">
         <span class="h1">
          APATHY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Apathy and abulia can be seen in patients with PD both in the context of depression and in the absence of other signs of clinical depression. Patients with PD who have apathy as a feature of depression should be treated with antidepressant medications and/or psychotherapy, as in other patients with depression. (See
         <a class="local">
          'Depression'
         </a>
         above.)
        </p>
        <p>
         There are no standardized treatments for apathy or abulia in the absence of depression or for persistent apathy despite treatment of depression. Based on results of a single small trial, the cholinesterase inhibitor
         <a class="drug drug_general" data-topicid="9529" href="/z/d/drug information/9529.html" rel="external">
          rivastigmine
         </a>
         may be considered [
         <a href="#rid1">
          1
         </a>
         ], even in those without depression or cognitive dysfunction [
         <a href="#rid36">
          36
         </a>
         ]. However, the clinical relevance and reproducibility of the changes observed in the trial are uncertain, and further studies are needed. Transcranial magnetic stimulation is under investigation as a treatment for apathy in PD, but evidence is limited [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         Worsened apathy can also be seen in patients with PD who undergo subthalamic nucleus deep brain stimulation. This is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/4897.html" rel="external">
          "Device-assisted and lesioning procedures for Parkinson disease", section on 'Complications and adverse effects'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H703449159">
         <span class="h1">
          ANXIETY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anxiety is common in patents with PD, occurring in over a third of patients. It may occur alone, or it may be comorbid with depression.
        </p>
        <p>
         Importantly, anxiety may be a symptom of wearing off of dopaminergic medication in patients who experience motor and nonmotor fluctuations [
         <a href="#rid38">
          38
         </a>
         ]. In such cases, management focuses primarily on levodopa dosing adjustments and other strategies to mitigate "wearing off" phenomena. Clinicians should also be aware that akathisia occurs in patients with PD and should be differentiated from anxiety, which may cause similar clinical manifestations. Like anxiety, akathisia may occur either spontaneously in patients with PD or due to end-of-dose levodopa withdrawal. (See
         <a class="medical medical_review" href="/z/d/html/4893.html" rel="external">
          "Medical management of motor fluctuations and dyskinesia in Parkinson disease", section on 'Approach to "wearing off"'
         </a>
         .)
        </p>
        <p>
         Evidence to guide the therapy of anxiety in the remaining patients with PD is limited and comes mainly from randomized trials for treatment of depression in PD, in which anxiety was a secondary outcome. A pooled analysis of these trials indicated some benefit from antidepressants on anxiety in PD [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         Selective serotonin reuptake inhibitors (SSRIs) such as
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         and
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         , serotonin-norepinephrine reuptake inhibitors (SNRIs) such as
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         and
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         , and serotonin-selective agents such as
         <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">
          buspirone
         </a>
         may all be considered. Doses and safety considerations do not differ from use of these agents for treatment of depression. (See
         <a class="local">
          'Safety considerations with SSRI use'
         </a>
         above.)
        </p>
        <p>
         Psychotherapy is also an option as an alternative or supplement to medications. In addition to trials in the general population, supporting evidence for psychotherapy includes a trial of cognitive-behavioral therapy (CBT) in 48 patients with PD and anxiety [
         <a href="#rid40">
          40
         </a>
         ]. There are data to indicate that transcranial magnetic stimulation may be a useful treatment for anxiety in patients with PD, especially when used in conjunction with medications [
         <a href="#rid28">
          28
         </a>
         ]. Other nonpharmacologic therapies such as yoga [
         <a href="#rid30">
          30,41
         </a>
         ], acupuncture [
         <a href="#rid42">
          42
         </a>
         ], and mindfulness-based interventions have not been well studied, but preliminary data suggest they may also be of utility [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14632.html" rel="external">
          "Generalized anxiety disorder in adults: Cognitive-behavioral therapy and other psychotherapies"
         </a>
         .)
        </p>
        <p>
         Therapeutic use of cannabinoids is of interest in patients with PD and nonmotor symptoms, especially anxiety and sleep disturbances. A small pilot trial of synthetic
         <a class="drug drug_general" data-topicid="9995" href="/z/d/drug information/9995.html" rel="external">
          nabilone
         </a>
         (not available in the United States) found potential benefits on anxiety, sleep, and pain symptoms, with similar adverse effects compared with placebo [
         <a href="#rid44">
          44
         </a>
         ]. In addition, a small randomized, placebo-controlled crossover study showed that a single dose of cannabidiol decreased anxiety symptoms including anxiety-related tremor in patients with PD [
         <a href="#rid45">
          45
         </a>
         ]. Beneficial effects on anxiety have also been observed in adults without PD [
         <a href="#rid46">
          46,47
         </a>
         ]. These preliminary findings are promising but require confirmation in larger studies before cannabinoids can be recommended for treatment of nonmotor symptoms in PD. Patients and clinicians should be aware of the potential for worsened cognitive function with daily use, as observed in a 16-week trial of a cannabidiol plus tetrahydrocannabinol formulation in 58 patients with PD [
         <a href="#rid48">
          48
         </a>
         ]. Additional considerations and guidance on use of
         <a class="drug drug_general" data-topicid="134930" href="/z/d/drug information/134930.html" rel="external">
          medical cannabis
         </a>
         are detailed separately. (See
         <a class="medical medical_review" href="/z/d/html/126970.html" rel="external">
          "Medical use of cannabis and cannabinoids in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H75564119">
         <span class="h1">
          COGNITIVE IMPAIRMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         While PD can coexist with other common causes of dementia, such as Alzheimer disease and vascular dementia, cognitive impairment and dementia are increasingly recognized as a common feature of PD itself. The diagnosis and management of dementia associated with PD are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5089.html" rel="external">
          "Cognitive impairment and dementia in Parkinson disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PSYCHOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H92830250">
         <span class="h2">
          Clinical manifestations and causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Psychosis is a frequent complication of PD. It is characterized mainly by visual hallucinations and delusions, which are often paranoid in content [
         <a href="#rid49">
          49
         </a>
         ]. Hallucinations are the most common manifestation, and they affect up to 40 percent of patients with PD, particularly those at an advanced stage of illness.
        </p>
        <p>
         The adverse effects of antiparkinson medications, the dopamine agonists in particular, are probably the most important cause of psychosis in patients with PD. Psychosis may also be triggered by infection, delirium, dementia, or medications. Underlying dementia predisposes to hallucinations and delusions, and psychosis is a risk factor for nursing home placement and mortality. (See
         <a class="medical medical_review" href="/z/d/html/4903.html" rel="external">
          "Clinical manifestations of Parkinson disease", section on 'Psychotic symptoms'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1124653245">
         <span class="h2">
          Evaluate and treat triggers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of psychosis in patients with PD  (
         <a class="graphic graphic_algorithm graphicRef110759" href="/z/d/graphic/110759.html" rel="external">
          algorithm 1
         </a>
         ) involves identifying and treating the underlying causes and contributory factors [
         <a href="#rid50">
          50
         </a>
         ], including general measures that are similar to the treatment of delirium. (See
         <a class="medical medical_review" href="/z/d/html/4823.html" rel="external">
          "Delirium and acute confusional states: Prevention, treatment, and prognosis"
         </a>
         .)
        </p>
        <p>
         Psychosis can be triggered by systemic conditions such as symptomatic or occult infection (eg, pneumonia or urinary tract infection), so this possibility should be investigated and treated if present [
         <a href="#rid50">
          50,51
         </a>
         ]. Anticholinergics can contribute to confusion and exacerbate psychosis in PD. Psychoactive medications, including sedatives, anxiolytics, and antidepressants, are potential culprits and should be reduced or stopped if possible.
        </p>
        <p class="headingAnchor" id="H1147858734">
         <span class="h2">
          Antiparkinson medication adjustments
         </span>
         <span class="headingEndMark">
          —
         </span>
         Stopping all potentially offending antiparkinson drugs is usually not an option, although dose reduction can frequently be accomplished with amelioration of hallucinations and little loss of drug-related benefit.
        </p>
        <p>
         Antiparkinsonian drugs may be reduced or stopped in an order that balances their potency as antiparkinson agents and their likelihood of exacerbating disabling hallucinations. Decisions regarding which drug to stop in this setting should also take into account which one drug might have triggered the psychosis. For example, if a patient's hallucinations began immediately after adding a catechol-O-methyl transferase (COMT) inhibitor to the combination of other drugs that had been previously well tolerated, then the COMT inhibitor should be stopped first.
        </p>
        <p>
         If a temporal relationship is not clear, the suggested sequence of discontinuation begins with anticholinergic drugs, followed by
         <a class="drug drug_general" data-topicid="8508" href="/z/d/drug information/8508.html" rel="external">
          amantadine
         </a>
         , dopamine agonists, monoamine oxidase type B (MAO B) inhibitors, and COMT inhibitors  (
         <a class="graphic graphic_algorithm graphicRef110759" href="/z/d/graphic/110759.html" rel="external">
          algorithm 1
         </a>
         ). Levodopa should be the last of a drug combination to be reduced, since it is the most effective antiparkinson agent and least likely to cause psychosis. However, if given in unusually high doses, it too might need to be reduced.
        </p>
        <p class="headingAnchor" id="H2244523323">
         <span class="h2">
          Role of cholinesterase inhibitors for dementia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the data are inconsistent, some studies have suggested a potential benefit of cholinesterase inhibitors for improvement in neuropsychiatric symptoms in patients with PD dementia and dementia with Lewy bodies [
         <a href="#rid1">
          1,52
         </a>
         ]. However, the effect size is small and may not be clinically significant. (See
         <a class="medical medical_review" href="/z/d/html/5082.html" rel="external">
          "Management of neuropsychiatric symptoms of dementia", section on 'Antidementia drugs'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H319618132">
         <span class="h2">
          Refractory psychotic symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with troublesome hallucinations or delusions despite antiparkinson medication adjustments, pharmacologic treatment directed at the psychotic symptoms may be necessary. If antipsychotic drugs are deemed necessary, preferred agents in patients with PD include
         <a class="drug drug_general" data-topicid="107981" href="/z/d/drug information/107981.html" rel="external">
          pimavanserin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         All antipsychotic drugs carry risk, including an association with a small increase in all-cause mortality and cardiovascular events when used to treat behavioral disorders in older adults with dementia. In patients with PD specifically, data also suggest that antipsychotic use is associated with an increased risk of mortality [
         <a href="#rid53">
          53
         </a>
         ] as well as morbidity and health care utilization [
         <a href="#rid54">
          54
         </a>
         ]. However, these risks must be balanced with the high morbidity and mortality of untreated psychosis [
         <a href="#rid7">
          7
         </a>
         ]. When the potential benefits are felt to outweigh the risks, antipsychotics should be prescribed cautiously, starting with low doses and using the lowest dose necessary to achieve clinical response. The need for ongoing dosing should be reviewed regularly. (See
         <a class="medical medical_review" href="/z/d/html/5082.html" rel="external">
          "Management of neuropsychiatric symptoms of dementia", section on 'Mortality risk'
         </a>
         .)
        </p>
        <p>
         Among antipsychotics,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         is widely prescribed in patients with PD and
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         may be the most effective, but the need for hematologic monitoring limited its use as a first-line option [
         <a href="#rid50">
          50,51,55-60
         </a>
         ].
         <a class="drug drug_general" data-topicid="107981" href="/z/d/drug information/107981.html" rel="external">
          Pimavanserin
         </a>
         is a newer alternative, and long-term safety and efficacy data are more limited. Due to limited head-to-head comparisons, treatment decisions should be individualized, taking into account these considerations as well as factors that are likely to vary by patient and region, such as drug costs. All three agents have a low likelihood of exacerbating parkinsonism, in contrast to the first-generation antipsychotics as well as other second-generation antipsychotics such as
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         and
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/117672.html" rel="external">
          "Drug-induced parkinsonism", section on 'Causative drugs'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pimavanserin
         </strong>
         –
         <a class="drug drug_general" data-topicid="107981" href="/z/d/drug information/107981.html" rel="external">
          Pimavanserin
         </a>
         is a second-generation antipsychotic drug that acts as a selective serotonin 5-HT2A receptor inverse agonist. It was approved by the US Food and Drug Administration in 2016 for treatment of psychosis in patients with PD but has not been approved in Europe. It has also been studied in dementia-related psychosis in patients with Alzheimer dementia as well as PD-associated dementia [
         <a href="#rid61">
          61
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5082.html" rel="external">
          "Management of neuropsychiatric symptoms of dementia", section on 'Clinical use'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dosing
         </strong>
         – The usual dose of
         <a class="drug drug_general" data-topicid="107981" href="/z/d/drug information/107981.html" rel="external">
          pimavanserin
         </a>
         is 34 mg daily (two 17 mg tablets or one 34 mg capsule taken once, in the morning).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adverse effects
         </strong>
         – The most common side effects are peripheral edema, nausea, and constipation. Rare but serious adverse effects include syncope, hypotension, and bradycardia. Like other antipsychotic drugs,
         <a class="drug drug_general" data-topicid="107981" href="/z/d/drug information/107981.html" rel="external">
          pimavanserin
         </a>
         is associated with QT prolongation. (See
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         There are also concerns that
         <a class="drug drug_general" data-topicid="107981" href="/z/d/drug information/107981.html" rel="external">
          pimavanserin
         </a>
         , like antipsychotic drugs more generally, may increase the risk of mortality in patients with PD. In an administrative claims database cohort study of &gt;20,000 adults ≥65 years of age with PD living in long-term care facilities in the United States, pimavanserin use, compared with nonuse, was associated with an increased risk of 30-day hospitalization (adjusted hazard ratio [aHR] 1.24, 95% CI 1.06-1.43) as well as mortality at multiple time points, including one year (aHR 1.56, 95% CI 1.42-1.72) [
         <a href="#rid62">
          62
         </a>
         ]. The study used inverse probability of treatment weighting to adjust for potential confounding, and sensitivity analyses using several other methods showed generally similar results. However, residual confounding remains possible based on the retrospective nature of the study. As discussed above, the possibility of harm should be discussed with patients and families and weighed against the risks of alternative therapies for psychosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Efficacy
         </strong>
         – Supportive evidence consists of a six-week randomized placebo-controlled trial of
         <a class="drug drug_general" data-topicid="107981" href="/z/d/drug information/107981.html" rel="external">
          pimavanserin
         </a>
         in 199 patients with PD-related psychosis [
         <a href="#rid63">
          63
         </a>
         ]. Compared with placebo, pimavanserin at 40 mg daily led to a 3-point greater reduction in scores on a 45-point PD-adapted scale for assessment of positive symptoms (PD-SAPS) from baseline to day 43. Treatment was not associated with worsening of motor symptoms. More patients discontinued therapy due to an adverse effect in the pimavanserin group (10 versus 2 patients), but the rate and type of individual adverse effects were otherwise balanced between treatment groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In an open-label follow-up study of patients enrolled in three randomized trials and a previous open-label study (n = 459, mean age 71 years, median follow-up 15 months), no new safety findings emerged, although a high rate of attrition over the course of the study limits confidence [
         <a href="#rid64">
          64
         </a>
         ]. Only 15 patients (3.3 percent) had adverse effects reported as serious and drug related, including syncope, hypotension, and bradycardia. The rate of significant QT prolongation (QTc &gt;500 milliseconds) over the course of the study was 2.6 percent. The overall rate of discontinuation at 48 months was 81 percent, most frequently voluntary (36 percent) or because of an adverse event (29 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Additional supporting evidence in patients with Alzheimer dementia and PD-associated dementia is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/5082.html" rel="external">
          "Management of neuropsychiatric symptoms of dementia", section on 'Efficacy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Quetiapine
         </strong>
         – Evidence for the efficacy of
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         in patients with PD is mixed [
         <a href="#rid15">
          15
         </a>
         ]. Supportive data include multiple observational studies, in which an improvement in psychosis was reported in approximately 80 percent of patients, and two partially blinded randomized trials comparing quetiapine and
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         showing similar efficacy for PD-related psychosis [
         <a href="#rid65">
          65
         </a>
         ]. However, only one of five small placebo-controlled trials has shown a benefit for quetiapine compared with placebo. Despite these inconsistent data, there seems to be some practical value of quetiapine in clinical practice, and it remains a widely used antipsychotic for dopaminergic-induced psychosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          Quetiapine
         </a>
         should be started at a low dose (eg, 12.5 mg at night) and may be titrated up to 100 mg at night according to response and tolerability. Quetiapine is sedating, and this property can be taken advantage of with evening/bedtime dosing to target exacerbation of confusion and psychosis with nightfall ("sundowning") and comorbid insomnia, when present. In some cases, evening/bedtime dosing is sufficient to control daytime psychotic symptoms, but in other cases, dosing during the day is required as well (usually in the morning, starting also at 12.5 mg and titrating upward as needed to a maximum of 100 mg). In such instances, daytime dosing can lead to or exacerbate daytime sleepiness, and the balance of risks and benefits must be continually reassessed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Like other antipsychotic drugs,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         is associated with QT prolongation. Additional side effects are reviewed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clozapine
         </strong>
         – Supportive evidence for
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         in patients with PD-related psychosis includes two four-week placebo-controlled trials as well as two smaller trials comparing clozapine and
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         [
         <a href="#rid60">
          60,66-68
         </a>
         ]. In the largest trial (n = 60), patients in the clozapine group had improved global impression scores, improved psychotic symptom assessment scores, and similar motor and cognitive function compared with patients in the placebo group [
         <a href="#rid60">
          60
         </a>
         ]. At the end of a 12-week open-label extension, approximately 50 percent of patients had complete recovery from delusions and hallucinations on clozapine.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          Clozapine
         </a>
         is also started at 12.5 mg at night and can be titrated up to 50 mg or more as needed. As with
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , a daytime dose can be added if needed to control daytime psychotic symptoms but may exacerbate daytime sleepiness.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          Clozapine
         </a>
         is underutilized because of the burdensome requirement of hematologic monitoring, but it is probably the most effective of the second-generation antipsychotics in this setting [
         <a href="#rid7">
          7,15,69
         </a>
         ]. Clozapine can cause granulocytopenia in 1 to 2 percent of patients, and weekly to biweekly blood counts are required by law in order for patients to use it. The risk of clozapine-induced leukopenia or agranulocytosis decreases exponentially over time, and the likelihood of developing fatal granulocytopenia beyond six months of clozapine treatment is almost nil [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Side effects, monitoring, and guidelines for administration of
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/14772.html" rel="external">
          "Schizophrenia in adults: Guidelines for prescribing clozapine"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4120318278">
         <span class="h1">
          INSOMNIA AND OTHER SLEEP DISORDERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Disorders of sleep are common in PD, including sleep onset and maintenance insomnia, restless legs syndrome (RLS), and rapid eye movement (REM) sleep behavior disorder (RBD). They affect between 55 and 80 percent of patients with PD. Management is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/133139.html" rel="external">
          "Evaluation and treatment of insomnia, daytime sleepiness, and other sleep disorders in Parkinson disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14894.html" rel="external">
          "Rapid eye movement sleep behavior disorder"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          DAYTIME SLEEPINESS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Excessive daytime sleepiness (EDS) is common in PD, and management requires a multipronged approach involving nonpharmacologic and pharmacologic strategies. An approach is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/133139.html" rel="external">
          "Evaluation and treatment of insomnia, daytime sleepiness, and other sleep disorders in Parkinson disease", section on 'Excessive daytime sleepiness'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          FATIGUE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fatigue is a common problem in patients with PD, and it appears to be an independent symptom of PD that overlaps with, but is not causally related to, depression and daytime sleepiness. (See
         <a class="medical medical_review" href="/z/d/html/4903.html" rel="external">
          "Clinical manifestations of Parkinson disease", section on 'Fatigue'
         </a>
         .)
        </p>
        <p>
         Treatment of fatigue in PD begins with an attempt to identify the cause. Excessive daytime sleepiness (EDS) and depression are both the most common and the most treatable identifiable causes (see
         <a class="local">
          'Daytime sleepiness'
         </a>
         above and
         <a class="local">
          'Depression'
         </a>
         above). Potentially reversible causes, such as hypothyroidism and medication side effects, should be investigated as well.
        </p>
        <p>
         Differentiating between sleepiness and fatigue is also important. True fatigue unassociated with sleepiness or depression is more difficult to treat. Suboptimally treated bradykinesia sometimes presents as subjective fatigue and should be identified and treated by readjusting antiparkinson medications. However, in some cases fatigue appears in patients with mild bradykinesia and is poorly understood.
        </p>
        <p>
         In the authors' clinical experience, no medications are reliably effective for fatigue in patients with PD, including
         <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">
          methylphenidate
         </a>
         or
         <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">
          modafinil
         </a>
         . However, it is not unreasonable to initiate a brief trial of these medications in selected patients, as a small subset may have a subjective response.
        </p>
        <p>
         Medications used for empiric treatment of fatigue, including
         <a class="drug drug_general" data-topicid="8508" href="/z/d/drug information/8508.html" rel="external">
          amantadine
         </a>
         and stimulants such as
         <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">
          methylphenidate
         </a>
         and pemoline, are options. However, the response to these is often disappointing [
         <a href="#rid71">
          71
         </a>
         ]. In one trial, 36 patients with PD were randomly assigned to treatment with either methylphenidate 10 mg three times daily or placebo [
         <a href="#rid72">
          72
         </a>
         ]. At six weeks, there was a significant reduction in two measures of self-reported fatigue for patients assigned to methylphenidate. Based upon the results of this trial, a practice parameter from the American Academy of Neurology (AAN) concluded that methylphenidate is "possibly useful" for treating fatigue in patients with PD [
         <a href="#rid73">
          73
         </a>
         ]. However, it is unclear whether the benefit of methylphenidate for fatigue in this setting is clinically meaningful.
        </p>
        <p>
         Of note,
         <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">
          modafinil
         </a>
         was not effective for improving either EDS (the primary outcome measure) or fatigue (a secondary outcome measure) in the randomized controlled trial cited above [
         <a href="#rid74">
          74
         </a>
         ]. (See
         <a class="local">
          'Daytime sleepiness'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2094502659">
         <span class="h1">
          DYSPHAGIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Swallowing difficulty is prevalent in PD, particularly at advanced stages. All phases of swallow are impacted due to abnormalities in both striated and smooth muscle function, ineffective tongue movements, delayed swallow responses, and weak cough-expectoration response. Dysphagia contributes to sialorrhea and increases risk of aspiration and pneumonia. (See
         <a class="medical medical_review" href="/z/d/html/85949.html" rel="external">
          "Swallowing disorders and aspiration in palliative care: Definition, pathophysiology, etiology, and consequences", section on 'Parkinson disease'
         </a>
         .)
        </p>
        <p>
         Dysphagia is important to recognize in patients with PD as there are compensatory strategies available to help retain safe and effective oral feeding for as long as possible. Assessment and management strategies are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/95508.html" rel="external">
          "Swallowing disorders and aspiration in palliative care: Assessment and strategies for management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2566898710">
         <span class="h1">
          AUTONOMIC DYSFUNCTION
         </span>
        </p>
        <p class="headingAnchor" id="H10643347">
         <span class="h2">
          Constipation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Constipation related to autonomic dysfunction and slowed colonic transit time is one of the most common nonmotor problems in patients with PD.
        </p>
        <p>
         Treatment of constipation in PD does not generally differ from the treatment of constipation in other patient populations. The approach includes patient education, behavior modification and dietary changes (eg, increased fluid and fiber intake), and laxative therapy beginning with bulk-forming laxatives. (See
         <a class="medical medical_review" href="/z/d/html/2636.html" rel="external">
          "Management of chronic constipation in adults"
         </a>
         .)
        </p>
        <p>
         Specifically in patients with PD, the following therapies have been studied and found to be more effective than placebo in small trials [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polyethylene glycol [
         <a href="#rid75">
          75
         </a>
         ], an osmotic laxative. (See
         <a class="medical medical_review" href="/z/d/html/2636.html" rel="external">
          "Management of chronic constipation in adults", section on 'Osmotic agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Probiotics, including fermented milk containing probiotic strains and prebiotic fiber [
         <a href="#rid76">
          76
         </a>
         ] and multistrain probiotic capsules [
         <a href="#rid77">
          77
         </a>
         ]. Larger studies of various probiotics for constipation in the general population support a benefit in some but not all trials. (See
         <a class="medical medical_review" href="/z/d/html/2603.html" rel="external">
          "Probiotics for gastrointestinal diseases", section on 'Constipation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10195" href="/z/d/drug information/10195.html" rel="external">
          Lubiprostone
         </a>
         , a locally acting chloride channel activator [
         <a href="#rid78">
          78
         </a>
         ]. Nausea is a common side effect of lubiprostone, and long-term safety has not been established. These factors limit use to patients with severe constipation in whom other approaches have been unsuccessful. (See
         <a class="medical medical_review" href="/z/d/html/2636.html" rel="external">
          "Management of chronic constipation in adults", section on 'Lubiprostone'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Alpha-synuclein aggregates have been identified in the enteric nervous system in individuals with PD, and therapies targeting gut pathologic alpha-synuclein are under investigation as a potential approach to improving enteric nervous system dysfunction. As an example, ENT-01 (squalamine phosphate) is an oral steroid-polyamine conjugate that displaces alpha-synuclein from enteric nerve cell membranes in preclinical models [
         <a href="#rid79">
          79,80
         </a>
         ]. In a phase 2b randomized trial involving 150 patients with PD and constipation, escalating daily doses of ENT-01 for 25 days improved the number of weekly bowel movements, stool consistency, and laxative use compared with placebo [
         <a href="#rid81">
          81
         </a>
         ]. Selected neurologic outcomes in a subset of patients also improved. Nausea and diarrhea were the most common side effects attributable to treatment. Further evidence on safety and efficacy is needed in a larger phase 3 study with a longer treatment period.
        </p>
        <p class="headingAnchor" id="H9049580">
         <span class="h2">
          Sialorrhea
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sialorrhea or drooling are common symptoms of PD related to reduced oromotor control and autonomic dysfunction. For patients with mild symptoms, the use of chewing gum or hard candy to encourage swallowing may reduce drooling in social situations [
         <a href="#rid82">
          82,83
         </a>
         ].
        </p>
        <p>
         For patients with more severe symptoms, treatment with botulinum toxin injections into the salivary glands can be effective and is well tolerated, with dry mouth occurring in approximately five percent or less of patients [
         <a href="#rid1">
          1,15,84-89
         </a>
         ].
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          Glycopyrrolate
         </a>
         (eg, 1 mg three times daily) is also effective [
         <a href="#rid15">
          15,90,91
         </a>
         ] and has only a limited ability to cross the blood-brain barrier, which may reduce the risk of central anticholinergic side effects. Other anticholinergic medications (eg, oral
         <a class="drug drug_general" data-topicid="8545" href="/z/d/drug information/8545.html" rel="external">
          hyoscyamine
         </a>
         and
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         ; sublingual
         <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">
          ipratropium
         </a>
         bromide and sublingual
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         [1 percent ophthalmic solution, one to two drops applied sublingually once or twice daily]) have also been used to control sialorrhea and drooling [
         <a href="#rid92">
          92,93
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H94122632">
         <span class="h2">
          Rhinorrhea
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rhinorrhea is another nonmotor complication of PD that is commonly triggered by eating certain foods (gustatory rhinorrhea). Affected patients report a profuse runny nose that is unrelated to allergy, upper respiratory infection, or sinus disease [
         <a href="#rid94">
          94-96
         </a>
         ].
        </p>
        <p>
         There is no proven treatment for gustatory rhinorrhea in PD, but limited data and clinical experience suggest that
         <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">
          ipratropium
         </a>
         nasal spray, an anticholinergic agent, is effective [
         <a href="#rid93">
          93
         </a>
         ]. Similar to the treatment of sialorrhea with anticholinergic agents, care should be exercised to watch for peripheral and central anticholinergic side effects.
        </p>
        <p class="headingAnchor" id="H967237662">
         <span class="h2">
          Sexual dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients may not spontaneously discuss sexual dysfunction, making it important for the clinician to bring up this topic.
        </p>
        <p>
         Sexual dysfunction can range from underactivity to hypersexuality and may affect up to 25 percent of patients with PD. Hypersexuality tends to occur more often in younger men and patients treated with dopamine agonist therapy or deep brain stimulation. (See
         <a class="medical medical_review" href="/z/d/html/4896.html" rel="external">
          "Initial pharmacologic treatment of Parkinson disease", section on 'Impulse control disorders'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4897.html" rel="external">
          "Device-assisted and lesioning procedures for Parkinson disease", section on 'Complications and adverse effects'
         </a>
         .)
        </p>
        <p>
         In some patients, improving motor function with dopaminergic treatment may lead to improved sexual function. Men with erectile dysfunction may benefit from treatment with
         <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">
          sildenafil
         </a>
         taken one hour prior to sex [
         <a href="#rid97">
          97
         </a>
         ]. Sildenafil should be used cautiously in patients with orthostatic hypotension [
         <a href="#rid1">
          1
         </a>
         ]. Other medications such as
         <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">
          tadalafil
         </a>
         and
         <a class="drug drug_general" data-topicid="10172" href="/z/d/drug information/10172.html" rel="external">
          vardenafil
         </a>
         appear to be effective as well. Intrapenile injections of vasoactive drugs are effective in treatment-refractory cases (see
         <a class="medical medical_review" href="/z/d/html/7469.html" rel="external">
          "Treatment of male sexual dysfunction"
         </a>
         ). Women may benefit from vaginal lubricants and urinating prior to sexual activity. (See
         <a class="medical medical_review" href="/z/d/html/5485.html" rel="external">
          "Overview of sexual dysfunction in females: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1496606332">
         <span class="h2">
          Orthostatic hypotension
         </span>
         <span class="headingEndMark">
          —
         </span>
         Orthostatic hypotension is common and disabling in PD, with a cumulative prevalence of approximately 60 percent. It may occur as a feature of the disease itself or the medications used to treat PD, including levodopa, dopamine agonists, and monoamine oxidase type B (MAO B) inhibitors. (See
         <a class="medical medical_review" href="/z/d/html/4903.html" rel="external">
          "Clinical manifestations of Parkinson disease", section on 'Autonomic dysfunction'
         </a>
         .)
        </p>
        <p>
         Treatment should be initiated in symptomatic cases. The approach is the same as that for other causes of neurogenic orthostatic hypotension and includes nonpharmacologic  (
         <a class="graphic graphic_table graphicRef130806" href="/z/d/graphic/130806.html" rel="external">
          table 1
         </a>
         ) and pharmacologic  (
         <a class="graphic graphic_table graphicRef130807" href="/z/d/graphic/130807.html" rel="external">
          table 2
         </a>
         ) measures as well as avoidance of aggravating medications  (
         <a class="graphic graphic_table graphicRef130809" href="/z/d/graphic/130809.html" rel="external">
          table 3
         </a>
         ), when possible. An approach to medication selection is presented in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef130808" href="/z/d/graphic/130808.html" rel="external">
          algorithm 2
         </a>
         ) and reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5105.html" rel="external">
          "Treatment of orthostatic and postprandial hypotension"
         </a>
         .)
        </p>
        <p>
         Patients should also be monitored for supine hypertension, which is common in PD and can result in end-organ damage. Suggested approaches to management are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/5105.html" rel="external">
          "Treatment of orthostatic and postprandial hypotension", section on 'Supine hypertension'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2279749824">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117215.html" rel="external">
          "Society guideline links: Parkinson disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20471915">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15524.html" rel="external">
          "Patient education: Parkinson disease (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3322983824">
         <span class="h1">
          PATIENT PERSPECTIVE TOPIC
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See
         <a class="medical medical_review" href="/z/d/html/132685.html" rel="external">
          "Patient perspective: Parkinson disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H103839407">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Depression
         </strong>
         – Depression is common in patients with Parkinson disease (PD) and associated with increased motor disability and decreased quality of life. (See
         <a class="local">
          'Depression'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antidepressant selection
         </strong>
         – In most patients with PD who desire drug therapy for depression, we suggest starting with a selective serotonin-norepinephrine reuptake inhibitor (SNRI) or a selective serotonin reuptake inhibitor (SSRI) rather than a tricyclic antidepressant (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Although comparative efficacy data are limited and mixed, the likelihood of adverse events is lower with SNRIs and SSRIs than with tricyclic antidepressants such as
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         . (See
         <a class="local">
          'Medication selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Precautions
         </strong>
         – When prescribing antidepressants in patients with PD, clinicians should be aware of the potential for QT interval prolongation, drug-drug interactions, worsening motor symptoms, exacerbation of restless legs syndrome (RLS) and rapid eye movement sleep behavior disorder (RBD), and the low but important risk of serotonin syndrome. (See
         <a class="local">
          'Safety considerations with SSRI use'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anxiety
         </strong>
         – Anxiety as a manifestation of wearing off of dopaminergic medication in patients who experience motor and nonmotor fluctuations should be managed with levodopa doing adjustments and other related strategies. In the remaining patients, pharmacologic options for anxiety include SSRIs, SNRIs, and
         <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">
          buspirone
         </a>
         , similar to the general population. (See
         <a class="local">
          'Anxiety'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Psychosis
         </strong>
         – Psychosis (mainly visual hallucinations and delusions) is a frequent complication of PD, especially in patients with cognitive dysfunction.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          General approach
         </strong>
         – Management involves identifying and treating the underlying causes and contributory factors, sequential decrease or elimination of potentially offending antiparkinson drugs as allowed by motor function, and symptomatic antipsychotic drug therapy for refractory symptoms  (
         <a class="graphic graphic_algorithm graphicRef110759" href="/z/d/graphic/110759.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Psychosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Risks of antipsychotic drugs
         </strong>
         – Chronic use of antipsychotic drugs has been associated with increased all-cause mortality and cardiovascular events in older adults with dementia as well as in patients with PD. When the potential benefits are felt to outweigh the risks, antipsychotics should be prescribed cautiously, starting with low doses and using the lowest dose necessary to achieve clinical response. (See
         <a class="local">
          'Refractory psychotic symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Preferred drugs, when necessary
         </strong>
         – When antipsychotic drugs are deemed necessary for PD-related psychosis, we suggest
         <a class="drug drug_general" data-topicid="107981" href="/z/d/drug information/107981.html" rel="external">
          pimavanserin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         rather than other antipsychotic drugs (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Second-generation antipsychotics are less likely to exacerbate parkinsonism than first-generation antipsychotics, and each of the drugs listed has at least some evidence of efficacy in patients with PD. The choice among them should be individualized. Clozapine may be the most effective antipsychotic of the three but requires hematologic monitoring. (See
         <a class="local">
          'Refractory psychotic symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Drugs to avoid
         </strong>
         – First-generation antipsychotics,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         , and
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         should be avoided because they have a well-established, high risk of worsening motor symptoms in patients with PD. (See
         <a class="medical medical_review" href="/z/d/html/117672.html" rel="external">
          "Drug-induced parkinsonism", section on 'Causative drugs'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sleep disorders
         </strong>
         – Insomnia, excessive daytime sleepiness (EDS), and rapid eye movement (REM) sleep behavior disorder (RBD) are very common in patients with PD. Evaluation and management are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/133139.html" rel="external">
          "Evaluation and treatment of insomnia, daytime sleepiness, and other sleep disorders in Parkinson disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Autonomic dysfunction
         </strong>
         – Patients with PD commonly require supportive management of autonomic dysfunction, including constipation, sialorrhea, rhinorrhea, sexual dysfunction, and orthostatic hypotension. Strategies are reviewed for each condition. (See
         <a class="local">
          'Autonomic dysfunction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1632209220">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Daniel Tarsy, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov Disord 2019; 34:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weintraub D, Aarsland D, Biundo R, et al. Management of psychiatric and cognitive complications in Parkinson's disease. BMJ 2022; 379:e068718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nazem S, Siderowf AD, Duda JE, et al. Suicidal and death ideation in Parkinson's disease. Mov Disord 2008; 23:1573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kummer A, Cardoso F, Teixeira AL. Suicidal ideation in Parkinson's disease. CNS Spectr 2009; 14:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen YY, Yu S, Hu YH, et al. Risk of Suicide Among Patients With Parkinson Disease. JAMA Psychiatry 2021; 78:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okun MS, Watts RL. Depression associated with Parkinson's disease: clinical features and treatment. Neurology 2002; 58:S63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66:996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serrano-Dueñas M. [A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson's disease]. Rev Neurol 2002; 35:1010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008; 23:850.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009; 72:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 2010; 75:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012; 78:1229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007; 68:1108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011; 26 Suppl 3:S42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bharucha KJ, Sethi KD. Complex movement disorders induced by fluoxetine. Mov Disord 1996; 11:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gormley N, Watters L, Lawlor BA. Extrapyramidal side-effects in elderly patients exposed to selective serotonin reuptake inhibitors. Human Psychpharmacology 1997; 12:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996; 57:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson's disease. Mov Disord 1997; 12:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dell'Agnello G, Ceravolo R, Nuti A, et al. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin Neuropharmacol 2001; 24:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montastruc JL, Fabre N, Blin O, et al. Does fluoxetine aggravate Parkinson's disease? A pilot prospective study. Mov Disord 1995; 10:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology 1997; 48:1070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waters CH. Fluoxetine and selegiline--lack of significant interaction. Can J Neurol Sci 1994; 21:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toyama SC, Iacono RP. Is it safe to combine a selective serotonin reuptake inhibitor with selegiline? Ann Pharmacother 1994; 28:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith KM, Eyal E, Weintraub D, ADAGIO Investigators. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. JAMA Neurol 2015; 72:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dobkin RD, Menza M, Allen LA, et al. Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. Am J Psychiatry 2011; 168:1066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dobkin RD, Mann SL, Gara MA, et al. Telephone-based cognitive behavioral therapy for depression in Parkinson disease: A randomized controlled trial. Neurology 2020; 94:e1764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng HB, Liu B, Shen J, et al. Non-invasive brain stimulation for treating psychiatric symptoms in Parkinson's disease: A systematic review and meta-analysis. J Clin Neurosci 2022; 106:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gollan R, Ernst M, Lieker E, et al. Effects of Resistance Training on Motor- and Non-Motor Symptoms in Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis. J Parkinsons Dis 2022; 12:1783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwok JYY, Choi EPH, Lee JJ, et al. Effects of Mindfulness Yoga Versus Conventional Physical Exercises on Symptom Experiences and Health-related Quality of Life in People with Parkinson's Disease: The Potential Mediating Roles of Anxiety and Depression. Ann Behav Med 2022; 56:1068.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim R, Lee TL, Lee H, et al. Effects of Exercise on Depressive Symptoms in Patients With Parkinson Disease: A Meta-analysis. Neurology 2023; 100:e377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feller D, Fox I, Gozzer P, et al. Exercise for Depressive Symptoms in Parkinson Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Arch Phys Med Rehabil 2023; 104:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun W, Yan J, Wu J, Ma H. Efficacy and Safety of Light Therapy as a Home Treatment for Motor and Non-Motor Symptoms of Parkinson Disease: A Meta-Analysis. Med Sci Monit 2022; 28:e935074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitarnun W, Mitranun W, Mitarnun W, Pangwong W. Home-Based Walking Meditation Decreases Disease Severity in Parkinson's Disease: A Randomized Controlled Trial. J Integr Complement Med 2022; 28:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Interian A, Miller RB, Hill LMS, et al. A Pilot Study of Telehealth Mindfulness-Based Cognitive Therapy for Depression in Parkinson's Disease. J Geriatr Psychiatry Neurol 2023; 36:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devos D, Moreau C, Maltête D, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry 2014; 85:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wei W, Yi X, Ruan J, et al. The efficacy of repetitive transcranial magnetic stimulation on emotional processing in apathetic patients with Parkinson's disease: A Placebo-controlled ERP study. J Affect Disord 2021; 282:776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Velden RMJ, Broen MPG, Kuijf ML, Leentjens AFG. Frequency of mood and anxiety fluctuations in Parkinson's disease patients with motor fluctuations: A systematic review. Mov Disord 2018; 33:1521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Troeung L, Egan SJ, Gasson N. A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease. PLoS One 2013; 8:e79510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moonen AJH, Mulders AEP, Defebvre L, et al. Cognitive Behavioral Therapy for Anxiety in Parkinson's Disease: A Randomized Controlled Trial. Mov Disord 2021; 36:2539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang Y, Wang G, Zhang S, et al. Efficacy and evaluation of therapeutic exercises on adults with Parkinson's disease: a systematic review and network meta-analysis. BMC Geriatr 2022; 22:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fan JQ, Lu WJ, Tan WQ, et al. Effectiveness of Acupuncture for Anxiety Among Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Netw Open 2022; 5:e2232133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghielen I, van Wegen EEH, Rutten S, et al. Body awareness training in the treatment of wearing-off related anxiety in patients with Parkinson's disease: Results from a pilot randomized controlled trial. J Psychosom Res 2017; 103:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peball M, Krismer F, Knaus HG, et al. Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone. Ann Neurol 2020; 88:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Faria SM, de Morais Fabrício D, Tumas V, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease. J Psychopharmacol 2020; 34:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry 2019; 6:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urbi B, Corbett J, Hughes I, et al. Effects of Cannabis in Parkinson's Disease: A Systematic Review and Meta-Analysis. J Parkinsons Dis 2022; 12:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Domen CH, Sillau S, Liu Y, et al. Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Δ9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms. Mov Disord 2023; 38:1341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol 2010; 67:996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman JH. Parkinson disease psychosis: Update. Behav Neurol 2013; 27:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connolly B, Fox SH. Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease. Neurotherapeutics 2014; 11:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           d'Angremont E, Begemann MJH, van Laar T, Sommer IEC. Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis. JAMA Neurol 2023; 80:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weintraub D, Chiang C, Kim HM, et al. Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease. JAMA Neurol 2016; 73:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weintraub D, Chiang C, Kim HM, et al. Antipsychotic Use and Physical Morbidity in Parkinson Disease. Am J Geriatr Psychiatry 2017; 25:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabey JM, Treves TA, Neufeld MY, et al. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 1995; 45:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 1999; 14:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgante L, Epifanio A, Spina E, et al. Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease. Neurol Sci 2002; 23 Suppl 2:S89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juncos JL, Roberts VJ, Evatt ML, et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord 2004; 19:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004; 75:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tariot PN, Cummings JL, Soto-Martin ME, et al. Trial of Pimavanserin in Dementia-Related Psychosis. N Engl J Med 2021; 385:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hwang YJ, Alexander GC, An H, et al. Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease. Neurology 2021; 97:e1266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014; 383:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballard CG, Kreitzman DL, Isaacson S, et al. Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis. Parkinsonism Relat Disord 2020; 77:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shotbolt P, Samuel M, David A. Quetiapine in the treatment of psychosis in Parkinson's disease. Ther Adv Neurol Disord 2010; 3:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Factor SA, Friedman JH, Lannon MC, et al. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 2001; 16:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merims D, Balas M, Peretz C, et al. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 2006; 29:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004; 27:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014; 311:1670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulte P. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother 2006; 40:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elbers RG, Verhoef J, van Wegen EE, et al. Interventions for fatigue in Parkinson's disease. Cochrane Database Syst Rev 2015; :CD010925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendonça DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord 2007; 22:2070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010; 74:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005; 76:1636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov Disord 2007; 22:1239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barichella M, Pacchetti C, Bolliri C, et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT. Neurology 2016; 87:1274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan AH, Lim SY, Chong KK, et al. Probiotics for Constipation in Parkinson Disease: A Randomized Placebo-Controlled Study. Neurology 2021; 96:e772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ondo WG, Kenney C, Sullivan K, et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology 2012; 78:1650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perni M, Galvagnion C, Maltsev A, et al. A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity. Proc Natl Acad Sci U S A 2017; 114:E1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           West CL, Mao YK, Delungahawatta T, et al. Squalamine Restores the Function of the Enteric Nervous System in Mouse Models of Parkinson's Disease. J Parkinsons Dis 2020; 10:1477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camilleri M, Subramanian T, Pagan F, et al. Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease : A Randomized Controlled Trial. Ann Intern Med 2022; 175:1666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2011; 17:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cloud LJ, Greene JG. Gastrointestinal features of Parkinson's disease. Curr Neurol Neurosci Rep 2011; 11:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chinnapongse R, Gullo K, Nemeth P, et al. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial. Mov Disord 2012; 27:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004; 62:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lagalla G, Millevolte M, Capecci M, et al. Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol 2009; 256:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lagalla G, Millevolte M, Capecci M, et al. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2006; 21:704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jost WH, Friedman A, Michel O, et al. SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. Neurology 2019; 92:e1982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isaacson SH, Ondo W, Jackson CE, et al. Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical Trial. JAMA Neurol 2020; 77:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arbouw ME, Movig KL, Koopmann M, et al. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology 2010; 74:1203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mestre TA, Freitas E, Basndwah A, et al. Glycopyrrolate Improves Disability From Sialorrhea in Parkinson's Disease: A 12-Week Controlled Trial. Mov Disord 2020; 35:2319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord 2002; 17:1318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomsen TR, Galpern WR, Asante A, et al. Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. Mov Disord 2007; 22:2268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman JH, Amick MM. Rhinorrhea is increased in Parkinson's disease. Mov Disord 2008; 23:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sedig L, Leibner J, Ramjit AL, et al. Is rhinorrhea an under-recognized intrinsic symptom of Parkinson disease? A prospective pilot study. Int J Neurosci 2010; 120:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chou KL, Koeppe RA, Bohnen NI. Rhinorrhea: a common nondopaminergic feature of Parkinson's disease. Mov Disord 2011; 26:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raffaele R, Vecchio I, Giammusso B, et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. Eur Urol 2002; 41:382.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4900 Version 53.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30653247" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36280256" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Management of psychiatric and cognitive complications in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18618660" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Suicidal and death ideation in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19890237" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Suicidal ideation in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33326004" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Risk of Suicide Among Patients With Parkinson Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11909987" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Depression associated with Parkinson's disease: clinical features and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16606910" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12497304" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : [A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson's disease].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18311826" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19092112" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A controlled trial of antidepressants in patients with Parkinson disease and depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20679638" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22496199" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17404192" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20452823" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22021174" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8723152" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Complex movement disorders induced by fluoxetine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Extrapyramidal side-effects in elderly patients exposed to selective serotonin reuptake inhibitors
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8909330" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Movement disorders associated with the serotonin selective reuptake inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9380061" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Sertraline for the treatment of depression in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11479393" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7651460" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Does fluoxetine aggravate Parkinson's disease? A pilot prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9109902" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8000982" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Fluoxetine and selegiline--lack of significant interaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8193438" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Is it safe to combine a selective serotonin reuptake inhibitor with selegiline?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25420207" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21676990" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32238507" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Telephone-based cognitive behavioral therapy for depression in Parkinson disease: A randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36274298" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Non-invasive brain stimulation for treating psychiatric symptoms in Parkinson's disease: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35754291" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Effects of Resistance Training on Motor- and Non-Motor Symptoms in Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35460239" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Effects of Mindfulness Yoga Versus Conventional Physical Exercises on Symptom Experiences and Health-related Quality of Life in People with Parkinson's Disease: The Potential Mediating Roles of Anxiety and Depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36220597" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Effects of Exercise on Depressive Symptoms in Patients With Parkinson Disease: A Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36030894" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Exercise for Depressive Symptoms in Parkinson Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34992207" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Efficacy and Safety of Light Therapy as a Home Treatment for Motor and Non-Motor Symptoms of Parkinson Disease: A Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35294297" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Home-Based Walking Meditation Decreases Disease Severity in Parkinson's Disease: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35603772" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A Pilot Study of Telehealth Mindfulness-Based Cognitive Therapy for Depression in Parkinson's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24218528" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33601718" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The efficacy of repetitive transcranial magnetic stimulation on emotional processing in apathetic patients with Parkinson's disease: A Placebo-controlled ERP study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30225905" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Frequency of mood and anxiety fluctuations in Parkinson's disease patients with motor fluctuations: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24236141" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33617699" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Cognitive Behavioral Therapy for Anxiety in Parkinson's Disease: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36271367" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Efficacy and evaluation of therapeutic exercises on adults with Parkinson's disease: a systematic review and network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36129711" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Effectiveness of Acupuncture for Anxiety Among Patients With Parkinson Disease: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29167034" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Body awareness training in the treatment of wearing-off related anxiety in patients with Parkinson's disease: Results from a pilot randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32757413" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31909680" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31672337" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34958046" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Effects of Cannabis in Parkinson's Disease: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37212386" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol andΔ9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20697051" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : A 12-year population-based study of psychosis in Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23242358" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Parkinson disease psychosis: Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24288035" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37358841" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26999262" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28259697" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Antipsychotic Use and Physical Morbidity in Parkinson Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7898690" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10348474" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10072410" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12548358" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14743357" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Quetiapine improves psychotic symptoms and cognition in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15090561" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34289275" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Trial of Pimavanserin in Dementia-Related Psychosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34389652" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24183563" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32712560" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21179595" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Quetiapine in the treatment of psychosis in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11215574" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17095896" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15319699" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24756517" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Pharmacological treatment of Parkinson disease: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16595571" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26447539" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Interventions for fatigue in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17674415" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20231670" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16291885" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17566120" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27543643" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33046607" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Probiotics for Constipation in Parkinson Disease: A Randomized Placebo-Controlled Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22573627" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28096355" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : A natural product inhibits the initiation ofα-synuclein aggregation and suppresses its toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32925094" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Squalamine Restores the Function of the Enteric Nervous System in Mouse Models of Parkinson's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36343348" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease : A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20829091" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Gastrointestinal dysfunction in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21499704" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Gastrointestinal features of Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21887710" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14718694" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19401804" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16440332" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30918101" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31930364" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20385892" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32657457" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Glycopyrrolate Improves Disability From Sialorrhea in Parkinson's Disease: A 12-Week Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12465075" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17876852" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18074378" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Rhinorrhea is increased in Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20374072" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Is rhinorrhea an under-recognized intrinsic symptom of Parkinson disease? A prospective pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20842685" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Rhinorrhea: a common nondopaminergic feature of Parkinson's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12074807" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
